MTOR and breast carcinoma: Meanwhile, although it is not understood whether AKT and mTOR are direct target molecules for MIT-1, Park et al. reported that NecroX-5, another family molecule of MIT-001 (previously known as NecroX-7), inhibited AKT via a reduction in the intracellular calcium levels in mouse breast cancer 4T1 cells and human breast cancer HCC70, MDA-MB-231, and MDA-MB-453 cells [51].